I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1 previous therapy
cholangiocarcinoma
measurable disease
systemic therapy
pemigatinib
non-resectable cholangiocarcinoma
- 0 views
- 19 Feb, 2024